ZM323881, a novel inhibitor of vascular endothelial growth factor-receptor-2 tyrosine kinase activity

Microcirculation

Volumn 9, Issue 6, 2002, Pages 513-522

  Whittles, C E ^a   Pocock, T M ^a   Wedge, S R ^b   Kendrew, J ^b   Hennequin, L F ^b   Harper, S J ^a   Bates, David O ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b ASTRAZENECA   (United Kingdom)

Author keywords

Angiogenesis; Endothelial cells; flk 1 KDR; flt 1; HUVEC; Vascular permeability; VEGF

Indexed keywords

ANIMALIA; ANURA;

EID: 0040078397     PISSN: 10739688     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.mn.7800164     Document Type: Article

References (35)

1. 1 Achen MG, Jeltsch M., Kukk E., Makinen T., Vitali A., Wilks AF, Alitalo K., Stacker SA. (1998). Vascular endothelial growth factor D (VEGF‐D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4). Proc Natl Acad Sci USA 95: 548–553.
2. 2 Basser R., Hurwitz H., Barge A., Davis I., DeBoer R., Holden S., McArthur G., McKinley M., Nairn K., Persky M., Rischin D., Rosenthal M., Swaisland H., Eckhardt G.. (2001). Phase 1 pharmacokinetic and biological study of the angiogenesis inhibitor, ZD6474, in patients with solid tumors. In: Proceedings of the 37th Annual Meeting of the American Society of Clinical Oncology. American Society of Clinical Oncology, San Francisco, USA.
3. 3 Bates DO, Curry FE. (1996). Vascular endothelial growth factor increases hydraulic conductivity of isolated perfused microvessels. Am J Physiol 271: H2520–H2528.
4. 4 Bates DO, Lodwick D., Williams B.. (1999). Vascular endothelial growth factor and microvascular permeability. Microcirculation 6: 83–96.
5. 5 Curry FE, Huxley VH, Sarelius IH. (1983). Techniques in microcirculation: measurement of permeability, pressure and flow. In: Cardiovascular Physiology. Techniques in the Life Sciences. Vol. P309. ( RJ Linden, ed.) Elsevier, New York: pp. 1–34.
6. 6 de Vries C., Escobedo JA, Ueno H., Houck K., Ferrara N., Williams LT. (1992). The fms‐like tyrosine kinase, a receptor for vascular endothelial growth factor. Science 255: 989–991.
7. 7 Drevs J., Hofmann I., Hugenschmidt H., Wittig C., Madjar H., Muller M., Wood J., Martiny‐Baron G., Unger C., Marme D.. (2000). Effects of PTK787/ZK 222584, a specific inhibitor of vascular endothelial growth factor receptor tyrosine kinases, on primary tumor, metastasis, vessel density, and blood flow in a murine renal cell carcinoma model. Cancer Res 60: 4819–4824.
8. 8 Flamme I., Breier G., Risau W.. (1995). Vascular endothelial growth factor (VEGF) and VEGF receptor 2 (flk‐1) are expressed during vasculogenesis and vascular differentiation in the quail embryo. Dev Biol 169: 699–712.
9. 9 Gordon MS, Margolin K., Talpaz M., Sledge GW Jr, Holmgren E., Benjamin R., Stalter S., Shak S., Adelman D.. (2001). Phase I safety and pharmacokinetic study of recombinant human anti‐vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol 19: 843–850.
10. 10 Guo D., Jia Q., Song HY, Warren RS, Donner DB. (1995). Vascular endothelial cell growth factor promotes tyrosine phosphorylation of mediators of signal transduction that contain SH2 domains. Association with endothelial cell proliferation. J Biol Chem 270: 6729–6733.
11. 11 Hargrave RW, Huxley VH, Thipakorn B.. (1995). Seasonal variations of capillary hydraulic conductivity and volume status. Am J Physiol 268: R468–R474.
12. 12 Hennequin LF, Thomas AP, Johnstone C., Stokes ES, Ple PA, Lohmann JJ, Ogilvie DJ, Dukes M., Wedge SR, Curwen JO, Kendrew J., Lambert‐van der Brempt C.. (1999). Design and structure‐activity relationship of a new class of potent VEGF receptor tyrosine kinase inhibitors. J Med Chem 42: 5369–5389.
13. 13 Hillman NJ, Whittles CE, Pocock TM, Williams B., Bates DO. (2001). Differential effects of vascular endothelial growth factor‐C and placental growth factor‐1 on the hydraulic conductivity of frog mesenteric capillaries. J Vasc Res 38: 176–186.
14. 14 Joukov V., Pajusola K., Kaipainen A., Chilov D., Lahtinen I., Kukk E., Saksela O., Kalkkinen N., Alitalo K.. (1996). A novel vascular endothelial growth factor, VEGF‐C, is a ligand for the Flt4 (VEGFR‐3) and KDR (VEGFR‐2) receptor tyrosine kinases. EMBO J 15: 290–298.
15. 15 Kendall RL, Wang G., DiSalvo J., Thomas KA. (1994). Specificity of vascular endothelial cell growth factor receptor ligand binding domains. Biochem Biophys Res Commun 201: 326–330.
16. 16 Kendall RL, Wang G., Thomas KA. (1996). Identification of a natural soluble form of the vascular endothelial growth factor receptor, FLT‐1, and its het‐erodimerization with KDR. Biochem Biophys Res Commun 226: 324–328.
17. 17 Ku DD, Zaleski JK, Liu S., Brock TA. (1993). Vascular endothelial growth factor induces EDRF‐dependent relaxation in coronary arteries. Am J Physiol 265: H586–H592.
18. 18 Lohmann J‐JM, Hennequin LFA, Thomas AP. 1999. Preparation and antiangiogenic and/or vascular permeability reducing effect of quinazoline derivatives. In: United States Patent Office. Zeneca Ltd, UK, USA.
19. 19 Michel CC, Curry FE. (1999). Microvascular permeability. Physiol Rev 79: 703–761.
20. 20 Michel CC, Mason JC, Curry FE, Tooke JE, Hunter PJ. (1974). A development of the Landis technique for measuring the filtration coefficient of individual capillaries in the frog mesentery. Q J Exp Phys Cog Med Sci 59: 283–309.
21. 21 Olofsson B., Jeltsch M., Eriksson U., Alitalo K.. (1999). Current biology of VEGF‐B and VEGF‐C. Curr Opin Biotechnol 10: 528–535.
22. 22 Olofsson B., Pajusola K., Kaipainen A., von Euler G., Joukov V., Saksela O., Orpana A., Pettersson RF, Alitalo K., Eriksson U.. (1996). Vascular endothelial growth factor B, a novel growth factor for endothelial cells. Proc Natl Acad Sci USA 93: 2576–2581.
23. 23 Park JE, Chen HH, Winer J., Houck KA, Ferrara N.. (1994). Placenta growth factor. Potentiation of vascular endothelial growth factor bioactivity, in vitro and in vivo, and high affinity binding to Flt‐1 but not to Flk‐1/KDR. J Biol Chem 269: 25646–25654.
24. 24 Pocock TM, Bates DO. (2001). In vivo mechanisms of vascular endothelial growth factor‐mediated increased hydraulic conductivity of Rana capillaries. J Physiol (Lond) 534: 479–488.
25. 25 Quinn TP, Peters KG, de Vries C., Ferrara N., Williams LT. (1993). Fetal liver kinase 1 is a receptor for vascular endothelial growth factor and is selectively expressed in vascular endothelium. Proc Natl Acad Sci USA 90: 7533–7537.
26. 26 Seetharam L., Gotoh N., Maru Y., Neufeld G., Yamaguchi S., Shibuya M.. (1995). A unique signal transduction from FLT tyrosine kinase, a receptor for vascular endothelial growth factor VEGF. Oncogene 10: 135–147.
27. 27 Senger DR, Connolly DT, van de Water L., Feder J., Dvorak HF. (1990). Purification and NH2‐terminal amino acid sequence of guinea pig tumor‐secreted vascular permeability factor. Cancer Res 50: 1774–1778.
28. 28 Stacker SA, Vitali A., Caesar C., Domagala T., Groenen LC, Nice E., Achen MG, Wilks AF. (1999). A mutant form of vascular endothelial growth factor (VEGF) that lacks VEGF receptor‐2 activation retains the ability to induce vascular permeability. J Biol Chem 274: 34884–34892.
29. 29 Waltenberger J., Claesson‐Welsh L., Siegbahn A., Shibuya M., Heldin CH. (1994). Different signal transduction properties of KDR and Flt1, two receptors for vascular endothelial growth factor. J Biol Chem 269: 26988–26995.
30. 30 Warner AJ, Lopez‐Dee J., Knight EL, Feramisco JR, Prigent SA. (2000). The Shc‐related adaptor protein, Sck, forms a complex with the vascular‐endothelial‐growth‐factor receptor KDR in transfected cells. Biochem J 347: 501–509.
31. 31 Wedge SR, Ogilvie DJ, Dukes M., Kendrew J., Curwen JO, Hennequin LF, Thomas AP, Stokes ES, Curry B., Richmond GH, Wadsworth PF. (2000). ZD4190: an orally active inhibitor of vascular endothelial growth factor signaling with broad‐spectrum antitumor efficacy. Cancer Res 60: 970–975.
32. 32 Wood JM, Bold G., Buchdunger E., Cozens R., Ferrari S., Frei J., Hofmann F., Mestan J., Mett H., O'Reilly T., Persohn E., Rosel J., Schnell C., Stover D., Theuer A., Towbin H., Wenger F., Woods‐Cook K., Menrad A., Siemeister G., Schirner M., Thierauch KH, Schneider MR, Drevs J., Martiny‐Baron G., Totzke F.. (2000). PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor‐induced responses and tumor growth after oral administration. Cancer Res 60: 2178–2189.
33. 33 Wu HM, Huang Q., Yuan Y., Granger HJ. (1996). VEGF induces NO‐dependent hyperpermeability in coronary venules. Am J Physiol 271: H2735–H2739.
34. 34 Xu L., Yoneda J., Herrera C., Wood J., Killion JJ, Fidler IJ. (2000). Inhibition of malignant ascites and growth of human ovarian carcinoma by oral administration of a potent inhibitor of the vascular endothelial growth factor receptor tyrosine kinases. Int J Oncol 16: 445–454.
35. 35 Yano S., Herbst RS, Shinohara H., Knighton B., Bucana CD, Killion JJ, Wood J., Fidler IJ. (2000). Treatment for malignant pleural effusion of human lung adeno‐carcinoma by inhibition of vascular endothelial growth factor receptor tyrosine kinase phosphorylation. Clin Cancer Res 6: 957–965.